In August, Pear Therapeutics, the company at the forefront of creating prescription software to treat health conditions, announced that it had landed a deal with Optum Rx, which administers pharmacy benefits for millions of people nationwide.
It was a coup for an 8-year-old company, which had recently announced its intention to go public in a $1.6 billion deal, despite projecting just $4 million in revenue for 2021. According to the celebratory announcement, Pear’s three commercial smartphone apps, which deliver cognitive behavioral therapy for the treatment of substance use disorder, opioid use disorder, and insomnia, would have “formulary availability” with the country’s third-largest pharmacy benefits manager.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
